Loading
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Previous close
$135.28
+$0.81 · +0.60%
Regular session · ET · Market data may be delayed.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Day range
Current $135.28
52-week range
Current $135.28
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
84
Deep Value
Sentiment
70
Bullish
Risk
60
Elevated Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Day range
Current $135.28
52-week range
Current $135.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.71B USD | 2.07B USD | 1.7B USD | 1.31B USD | 1.1B USD |
| Cost of goods sold | 768.2M USD | 625.9M USD | 537.2M USD | 499.7M USD | 346.7M USD |
| Gross profit | 1.94B USD | 1.45B USD | 1.16B USD | 805.6M USD | 752.1M USD |
| Research and development | 301.1M USD | 219.6M USD | 205M USD | 180.2M USD | 160.1M USD |
| Selling, general, and administrative | 1.17B USD | 917.2M USD | 734.9M USD | 587.8M USD | 466M USD |
| Operating expenses | 1.47B USD | 1.14B USD | 939.9M USD | 768M USD | 626.1M USD |
| Interest income | 34.7M USD | 39.5M USD | 28.6M USD | 9.3M USD | 500K USD |
| Interest expense | 79.7M USD | 42.7M USD | 36.2M USD | 36M USD | 61.7M USD |
| Depreciation and amortization | 90.4M USD | 80.8M USD | 72.8M USD | 63.2M USD | 57.4M USD |
| Operating income | 473.8M USD | 308.9M USD | 220M USD | 37.6M USD | 126M USD |
| Net income | 247.1M USD | 418.3M USD | 206.3M USD | 4.6M USD | 16.8M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$182.35
34.79% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T18.05B0.01%129.34T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI327.61M0.01%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO273.09M0.02%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB236.88M0.13%185.3B USD0.03%$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP192.57M0.20%96.75B USD0.20%$213.04+0.55%
Vanguard Morningstar Small-Cap Growth ETFVBK136.02M0.30%44.7B USD0.05%$344.74+1.22%
iShares Core S&P 500 ETFIVV124.12M0.01%892.79B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY114.01M0.01%817.2B USD0.09%$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Small-Cap Growth ETFVBKiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
